BIOCON LTD

Biocon is engaged in the business of manufacture of biotechnology products and research services.

Key business

Biosimilars

Research Services

Generics

Novel Biologics

Shareholding Pattern

-PUBLIC GROUP

-PROMOTER GROUP

Financial Summary

Synopsis of Financials

• 9% year-on-year revenue growth in Q4 with impact of lower demand for research services in the U.S.
• Acquisition of biologics manufacturing facility from Stelis Biopharma.
• Diverse business platform with strong growth in biomanufacturing.
• Acquisition of land in Genome Valley in Hyderabad for long-term growth.
• Expected completion of facility modifications and qualification in fiscal ’25.
• Encouraging new funding in the U.S. biotech sector.
• Syngene expects revenue growth at single digit to low double digits for fiscal ’25 on a constant currency basis.
• Operating EBITDA margin to be similar to fiscal ’24 levels.
• Net profit growth expected in single digits.
• Overall Performance:
• Balanced progress in all core business verticals with operational successes and advances in preparation for future growth.
• Facing and addressing operational challenges.
• Positive momentum across Generics, Biosimilars, and Syngene.
• Expectations for growth opportunities in the near term and beyond.
• Strong focus on new product launches, market expansion, and cost control initiatives.

Final Outlook

Descending Channel Pattern:

Biocon’s price is moving within a descending channel, indicating a bearish trend in the short term. The upper and lower channel lines provide resistance and support levels, respectively. It recently touched the lower boundary of this channel near the ₹315 support level and bounced slightly, which suggests some buying interest at this level.

Support and Resistance Levels:

Support: The primary support level lies around ₹305, and a secondary support zone is observed near ₹315 (within the grey shaded area), which has acted as a strong buying zone historically.

Resistance: The price has resistance around ₹340.70 and ₹367.30. A break above these levels could indicate a potential reversal in the downtrend.

Exponential Moving Averages (EMA):

The chart displays the 9-day and 20-day EMAs, with the 9-day EMA currently around ₹328.43 and the 20-day EMA around ₹338.21.

Since the 9-day EMA is below the 20-day EMA, it signals bearish momentum. A crossover above the 20-day EMA could signal the start of a bullish reversal.

Volume Analysis:

Volume levels (shown as bars at the bottom) indicate trading interest. Although volume has picked up slightly, it’s still not at levels that might suggest a strong trend reversal.

Higher volume on green candles could indicate accumulating interest from buyers, especially if the price breaks above key resistance.

I will give Sell Recommendation for this stock